Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Boehringer Ingelheim
Chinese Patent Office
Daiichi Sankyo
Fuji

Generated: September 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,468,598

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,468,598 protect, and when does it expire?

Patent 9,468,598 protects DALIRESP and is included in one NDA.

This patent has fifty-two patent family members in thirty-five countries.

Summary for Patent: 9,468,598
Title:Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
Inventor(s): Dietrich; Rango (Constance, DE), Eistetter; Klaus (Constance, DE), Ney; Hartmut (Constance, DE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:13/874,065
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Drugs Protected by US Patent 9,468,598

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-002 Jan 23, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,468,598

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 07 160Feb 20, 2002
02003811Feb 20, 2002

International Family Members for US Patent 9,468,598

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038527 ➤ Sign Up
Austria 550038 ➤ Sign Up
Australia 2003206924 ➤ Sign Up
Brazil 0307739 ➤ Sign Up
Canada 2475923 ➤ Sign Up
China 102764242 ➤ Sign Up
China 1635909 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Colorcon
Mallinckrodt
Medtronic
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.